NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

It was not a hold, it was a partial hold, which is very different. And it was not for safety reasons, the end result being they were short placebo patients, and placebo patients, by being denied immediate access to DCVax-L, lived demonstrably less time even though upon recurrence, they lived longer than other patients that had recurred. Delaying access was detrimental to their longevity and unnecessary if having crossed over placebo patients ends up creating a trial with no placebo arm anyway.